BioAtla, Inc. (NASDAQ:BCAB) Short Interest Down 29.9% in December

BioAtla, Inc. (NASDAQ:BCAB) was the target of a large decrease in short interest in the month of December. As of December 15th, there was short interest totaling 4,341,741 shares, a decrease of 29.9% from the November 30th total of 6,190,599 shares. Currently, 8.4% of the company’s shares are sold short. Based on an average daily volume of 989,384 shares, the days-to-cover ratio is presently 4.4 days. Based on an average daily volume of 989,384 shares, the days-to-cover ratio is presently 4.4 days. Currently, 8.4% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of BioAtla in a report on Tuesday, October 14th. Wall Street Zen upgraded shares of BioAtla to a “sell” rating in a research report on Saturday, September 6th. Three research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce”.

Institutional Investors Weigh In On BioAtla

Several large investors have recently added to or reduced their stakes in BCAB. Woodline Partners LP purchased a new position in BioAtla in the 1st quarter valued at approximately $26,000. Acadian Asset Management LLC increased its position in shares of BioAtla by 968.9% during the first quarter. Acadian Asset Management LLC now owns 1,690,110 shares of the company’s stock worth $585,000 after acquiring an additional 1,531,994 shares during the period. Acorn Capital Advisors LLC raised its stake in shares of BioAtla by 19.9% in the second quarter. Acorn Capital Advisors LLC now owns 4,835,111 shares of the company’s stock valued at $1,915,000 after acquiring an additional 803,065 shares in the last quarter. Sheets Smith Investment Management purchased a new position in BioAtla in the third quarter valued at $46,000. Finally, Vanguard Group Inc. grew its stake in BioAtla by 9.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,945,795 shares of the company’s stock worth $1,339,000 after purchasing an additional 162,647 shares in the last quarter. 77.23% of the stock is owned by hedge funds and other institutional investors.

BioAtla Trading Down 6.1%

Shares of NASDAQ BCAB opened at $0.78 on Tuesday. The stock has a market capitalization of $46.08 million, a PE ratio of -0.68 and a beta of 1.00. BioAtla has a twelve month low of $0.24 and a twelve month high of $1.43. The stock has a fifty day simple moving average of $0.79 and a 200-day simple moving average of $0.60.

BioAtla (NASDAQ:BCAB) last announced its earnings results on Thursday, November 13th. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.04. On average, equities analysts predict that BioAtla will post -1.46 earnings per share for the current year.

BioAtla Company Profile

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.